deals, Life Sciences, Sepsis
Artisan Raises $9.4M in Debt Round
Ryan McBride 5/13/09
Artisan Pharma, a Waltham, MA-based developer of a biotech drug for a blood-clotting condition in sepsis patients, has raised $9.4 million of an $11.8 million round of debt financing, the firm reported yesterday in an SEC filing. The filing did not specify the investors in the debt round, which may also include the sale of warrants and options to buy equity in Artisan. Artisan says its lead drug, recombinant thrombomodulin, was licensed from Tokyo-based Asahi Kasei Pharma to develop the treatment in non-Asian markets.
Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.
5/13/09 8:48 pm
[...] Artisan Pharma has raised $9.4M of an $11.8M round of debt financing. Artisan’s lead drug is recombinant thrombomodulin, an anticlotting drug licensed from Asahi Kasei Pharma. Investors were not disclosed. [Xconomy] [...]